Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome
Amgen and The University of Texas MD Anderson Cancer Center have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells.
The research agreement will identify targets for this therapy in myelodysplastic syndrome (MDS), a bone marrow disorder in which the body does not produce sufficient healthy blood cells. MDS affects primarily older adults over age 60 and can cause severe anemia, potentially leading to development of acute myelogenous leukemia (AML), a blood cell cancer.
"This is a unique collaboration that explores BiTE therapy for its potential in treating a disorder that affects thousands of people each year," said Guillermo Garcia-Manero, professor of leukemia at MD Anderson. "At MD Anderson, we have unrivaled proteomics capabilities to explore new targets for this disease, and this novel approach may very well open up new potential treatments for our patients."
The collaboration's innovative approach will draw on the expertise of MD Anderson's Moon Shots Program, which aims to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths. Garcia-Manero leads the MDS/AML Moon Shots Program.
The collaborative agreement will allow Amgen and MD Anderson to join forces in a research partnership that aims to take new drug development from "A to Z." The agreement provides for joint development of new agents under pre-determined terms. Amgen retains all commercial rights, while MD Anderson is eligible to receive milestones and royalties upon successful achievement of key objectives.
"We are excited about the new research opportunities this collaboration will open up in further exploring the potential of BiTE technology," said Sean E. Harper, executive vice president of R&D at Amgen. "BiTE antibody constructs represent an innovative immunotherapy approach that helps the body's immune system target cancer cells. MD Anderson is a great partner in our quest to find potential new treatments for patients with serious illnesses."
BiTE antibody constructs are recombinant proteins consisting of two separate antibodies held together by a flexible peptide linker or bands of amino acids. The antibodies are designed to function as a link between T cells and cancer cells. One antibody or protein domain binds to the cancer cell's surface, while the other binds to the CD3 on the T cell, resulting in the malignant cell's death. It is thought that BiTE antibody constructs may be engineered to target a range of tumours.
"This long-term collaboration between leading scientists at MD Anderson and Amgen takes advantage of significant advances in technologies available for target discovery through the MD Anderson Moon Shots Program," said Samir Hanash, professor of clinical cancer prevention and director, the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer at MD Anderson. "The agreement covers the full scope of clinical development from identifying targets for this therapy in MDS to developing fully tested and approved new therapies."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance